Overview:

Stools tests are performed to diagnose the GI tract disorders and aid in the detection of parasites infection, bleeding obstruction, and inflammation. Stools tests can further be utilized for diagnosis of colorectal cancer or presence of pathogens such as Rotavirus, C. difficile, H. pylori among others in the GI tract. Laboratory tests used for the stool testing are either microbial particle-based or antibody-based, which include chemiluminescence immunoassays (CLIA), immunoassay and molecular diagnostic testing.

Increased incidence of C. difficile infections and other gastrointestinal diseases increases the demand for stool tests, thereby driving the global GI stool testing market. According to the Centers for Disease Control and Prevention, in 2014, an estimated of 14.8 million adults were diagnosed with ulcers and other digestive disorders in the United States. Furthermore, in 2017, 135,430 new cases of colorectal cancer were diagnosed in the country, raising the demand for GI stool testing. However, the challenge of accurate testing restrains the market.

The global GI stool testing market is segmented based on product type, application, test type, end-user, and geography. Among product types, reagents segment dominated the global market in 2017 with over 60% of the market share. Among applications, the GI tract infections segment led the global market in 2017 owing to high prevalent cases and increased awareness regarding the gastrointestinal disorders. Based on end-users, hospitals will continue to dominate the market owing to the high procedural load of the tests.

North America is anticipated to lead the global market owing to the high awareness of the gastrointestinal disorders and availability of evolved healthcare infrastructure. Manufacturers are focusing on the emerging markets including the Asia Pacific and Latin America due to the presence of potential opportunities.

The Global GI Stool Testing Market is segmented on the following bases:

• Global GI Stool Testing Market, by Product Type, 2016-2026 (US$ Mn)
  • Reagents
  • Instruments
• Global GI Stool Testing Market, by Application, 2016-2026 (US$ Mn)
  • Colorectal Cancer
  • Diarrhea
  • GI Tract Infections
  • Others (Poor Absorption Problems, Parasites)
• Global GI Stool Testing Market, by Test Type, 2016-2026 (US$ Mn)
  • Microscopy Tests
  • Culture Tests
  • Ova & Parasites Test
  • Occult Blood test
    • Immuno-FOB ELISA Test
    • Lateral Flow Immuno-FOB Test
    • Immuno-FOB agglutination test
    • Guaiac FOB Stool Test
  • Stool Biomarkers Tests
    • M2-PK Stool Test
    • Cologuard
  • Others (FIT (Fecal Immunochemical Test), Stool Fat Testing)
• Global GI Stool Testing Market, by End-user, 2016-2026 (US$ Mn)
  • Hospitals
  • Diagnostics Centers and Laboratories
  • Research Centers and Academic Institutions\
• Global GI Stool Testing Market, by Geography, 2016-2026 (US$ Mn)
  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • Rest of APAC
  • Latin America (LATAM)
    • Brazil
    • Mexico
    • Rest of LATAM
  • Middle East and Africa (MEA)
    • GCC
    • Rest of MEA

Key Players Identified in GI Stool Testing Market include:

Abbott Laboratories, Alere, Inc., Beckman Coulter, Inc., BioMrieux, Inc., Bio-Rad Laboratories, Cenogenics Corporation, DiaSorin S.p.A., Meridian Bioscience, Inc., Quest Diagnostics Incorporated, and Siemens Healthcare.

This report offers:

• A detailed outlook and current dynamics of the global GI stool testing market along with future trends.
• Market estimations of the global GI stool testing for the span of 10 years from 2016 to 2026
• Global GI stool testing market elucidation at granular level by segmentation of market based on various parameters.
• Profiling of the key players operating in the GI stool testing market along with graphical positioning of the major players